In Brief: J&J Snags NeoStrata; FDA Sets ICCR Prep; IRI Names Pacesetters
This article was originally published in The Rose Sheet
Executive Summary
Johnson & Johnson says its acquisition of NeoStrata will complement its existing skin-care portfolio. Meanwhile, FDA seeks public input at a meeting in advance of the upcoming International Cooperation on Cosmetics Regulation. More news in brief.
You may also be interested in...
J&J Launches Neutrogena Bright Boost, Children's Tylenol Dissolve Packs
Neutrogena Bright Boost line launches with technology borrowed from J&J's recently acquired NeoStrata high-end skin care line, worldwide consumer health chief Thibaut Mongon says. J&J also launches Children’s Tylenol Dissolve Packs.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.